Advanced glycated end-products affect HIF-transcriptional activity in renal cells

Molecular Endocrinology

Volumn 27, Issue 11, 2013, Pages 1918-1933

  Bondeva, Tzvetanka ^a   Heinzig, Juliane ^a   Ruhe, Carola ^a   Wolf, Gunter ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ANTIBODY; HIF 1 ALPHA PROTEIN; HIF 2 ALPHA PROTEIN; MESSENGER RNA; PLACEBO; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROTEIN; STREPTOZOCIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; ASSAY; CELL DIFFERENTIATION; CELL TYPE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DIABETIC NEPHROPATHY; ENZYME ACTIVITY; GEL MOBILITY SHIFT ASSAY; KIDNEY CELL; MESANGIUM CELL; MOUSE; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPORTER GENE; WILD TYPE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CELLS, CULTURED; DIABETES MELLITUS, EXPERIMENTAL; GLYCOSYLATION END PRODUCTS, ADVANCED; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PODOCYTES; PROCOLLAGEN-PROLINE DIOXYGENASE; RECEPTORS, IMMUNOLOGIC; SERUM ALBUMIN, BOVINE; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ACTIVATION;

EID: 84886387210     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2013-1036     Document Type: Article

References (56)

1. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988;318:1315-1321.
2. Brownlee M, Cerami A, Vlassara H. Advanced products of nonenzymatic glycosylation and the pathogenesis of diabetic vascular disease. Diabetes Metab Rev. 1988;4:437-451.
3. Fu MX, Wells-Knecht KJ, Blackledge JA, Lyons TJ, Thorpe SR, Baynes JW. Glycation, glycoxidation, and cross-linking of collagen by glucose. Kinetics, mechanisms, and inhibition of late stages of the Maillard reaction. Diabetes. 1994;43:676-683.
4. Busch M, Franke S, Ruster C, Wolf G. Advanced glycation end-products and the kidney. Eur J Clin Invest. 2010;40:742-755.
5. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54:1615-1625.
6. Kilhovd BK, Giardino I, Torjesen PA, et al. Increased serum levels of the specific AGE-compound methylglyoxal-derived hydroimidazolone in patients with type 2 diabetes. Metabolism. 2003;52:163-167.
7. Schleicher E, Wieland OH. Protein glycation: measurement and clinical relevance. J Clin Chem Clin Biochem. 1989;27:577-587.
8. Cohen MP, Ziyadeh FN. Role of Amadori-modified nonenzymatically glycated serum proteins in the pathogenesis of diabetic nephropathy. J Am Soc Nephrol. 1996;7:183-190.
9. Bierhaus A, Humpert PM, Morcos M, et al. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med (Berl). 2005;83:876-886.
10. Semba RD, Fink JC, Sun K, Bandinelli S, Guralnik JM, Ferrucci L. Carboxymethyl-lysine, an advanced glycation end product, and decline of renal function in older community-dwelling adults. Eur J Nutr. 2009;48:38-44.
11. Sakaguchi T, Yan SF, Yan SD, et al. Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest. 2003; 111:959-972.
12. Semba RD, Najjar SS, Sun K, Lakatta EG, Ferrucci L. Serum carboxymethyl-lysine, an advanced glycation end product, is associated with increased aortic pulse wave velocity in adults. Am J Hypertens. 2009;22:74-79.
13. Piarulli F, Lapolla A, Ragazzi E, et al. Role of endogenous secretory RAGE (esRAGE) in defending against plaque formation induced by oxidative stress in type 2 diabetic patients. Atherosclerosis. 2013; 226:252-257.
14. Lipscomb EA, Sarmiere PD, Freeman RS. SM-20 is a novel mitochondrial protein that causes caspase-dependent cell death in nerve growth factor-dependent neurons. J Biol Chem. 2001;276:5085-5092.
15. Hofmann MA, Drury S, Fu C, et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell. 1999;97:889-901.
16. van Beijnum JR, Buurman WA, Griffioen AW. Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis. 2008;11:91-99.
17. Lin L, Park S, Lakatta EG. RAGE signaling in inflammation and arterial aging. Front Biosci. 2009;14:1403-1413.
18. Cipollone F, Iezzi A, et al. The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation. 2003;108:1070-1077.
19. Haslbeck KM, Schleicher E, Bierhaus A, et al. The AGE/RAGE/ NF-κB pathway may contribute to the pathogenesis of polyneuropathy in impaired glucose tolerance (IGT). Exp Clin Endocrinol Diabetes. 2005;113:288-291.
20. Haslbeck KM, Friess U, Schleicher ED, et al. The RAGE pathway in inflammatory myopathies and limb girdle muscular dystrophy. Acta Neuropathol. 2005;110:247-254.
21. Franke S, Sommer M, Ruster C, Bondeva T, Marticke J, Hofmann G, Hein G, Wolf G. Advanced glycation end products induce cell cycle arrest and proinflammatory changes in osteoarthritic fibroblast-like synovial cells. Arthritis Res Ther. 2009;11:R136.
22. Hopfer U, Hopfer H, Jablonski K, Stahl RA, Wolf G. The novel WD-repeat protein Morg1 acts as a molecular scaffold for hypoxiainducible factor prolyl hydroxylase 3 (PHD3). J Biol Chem. 2006; 281:8645-8655.
23. Hirsila M, Koivunen P, Gunzler V, Kivirikko KI, Myllyharju J. Characterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor. J Biol Chem. 2003;278:30772-30780.
24. Bondeva T, Heinzig J, Franke S, Wolf G. Angiotensin II differentially regulates Morg1 expression in kidney cells. Am J Nephrol. 2012;35:442-455.
25. Hammerschmidt E, Loeffler I, Wolf G. Morg1 heterozygous mice are protected from acute renal ischemia-reperfusion injury. Am J Physiol Renal Physiol. 2009;297:F1273-F1287.
26. Stahr A, Frahm C, Kretz A, Bondeva T, Witte OW, Wolf G. Morg1(/) heterozygous mice are protected from experimentally induced focal cerebral ischemia. Brain Res. 2012;1482:22-31.
27. Wolf G, Haberstroh U, Neilson EG. Angiotensin II stimulates the proliferation and biosynthesis of type I collagen in cultured murine mesangial cells. Am J Pathol. 1992;140:95-107.
28. Haverty TP, Kelly CJ, Hines WH, et al. Characterization of a renal tubular epithelial cell line which secretes the autologous target antigen of autoimmune experimental interstitial nephritis. J Cell Biol. 1988;107:1359-1368.
29. Mundel P, Kriz W. Cell culture of podocytes. Exp Nephrol. 1996; 4:263-266.
30. Tesch GH, Allen TJ. Rodent models of streptozotocin-induced diabetic nephropathy. Nephrology (Carlton). 2007;12:261-266.
31. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2[-C(T)] method. Methods. 2001;25:402-408.
32. Bondeva T, Roger T, Wolf G. Differential regulation of Toll-like receptor 4 gene expression in renal cells by angiotensin II: dependency on AP1 and PU.1 transcriptional sites. Am J Nephrol. 2007; 27:308-314.
33. Bondeva T, Wolf G. Advanced glycation end products suppress neuropilin-1 expression in podocytes by a reduction in Sp1-dependent transcriptional activity. Am J Nephrol. 2009;30:336-345.
34. Neeper M, Schmidt AM, Brett J, et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem. 1992;267:14998-15004.
35. Brett J, Schmidt AM, Yan SD, et al. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol. 1993;143:1699-1712.
36. Ramasamy R, Yan SF, Schmidt AM. Receptor for AGE (RAGE): signaling mechanisms in the pathogenesis of diabetes and its complications. Ann NY Acad Sci. 2008;1243:88-102.
37. Lindsey JB, Cipollone F, Abdullah SM, McGuire DK. Receptor for advanced glycation end-products (RAGE) and soluble RAGE (sRAGE): cardiovascular implications. Diab Vasc Dis Res. 2009;6: 7-14.
38. Tekabe Y, Luma J, Li Q, Schmidt AM, Ramasamy R, Johnson LL. Imaging of receptors for advanced glycation end products in experimental myocardial ischemia and reperfusion injury. JACC Cardiovasc Imaging. 2012;5:59-67.
39. Schleicher ED, Wagner E, Nerlich AG. Increased accumulation of the glycoxidation product N-(carboxymethyl)lysine in human tissues in diabetes and aging. J Clin Invest. 1997;99:457-468.
40. Wang Z, Jiang Y, Liu N, et al. Advanced glycation end-product N-carboxymethyl-lysine accelerates progression of atherosclerotic calcification in diabetes. Atherosclerosis. 2012;221:387-396.
41. Tekabe Y, Li Q, Rosario R, et al. Development of receptor for advanced glycation end products-directed imaging of atherosclerotic plaque in a murine model of spontaneous atherosclerosis. Circ Cardiovasc Imaging. 2008;1:212-219.
42. Bernhardt WM, Campean V, Kany S, et al. Preconditional activation of hypoxia-inducible factors ameliorates ischemic acute renal failure. J Am Soc Nephrol. 2006;17:1970-1978.
43. Weidemann A, Bernhardt WM, Klanke B, et al. HIF activation protects from acute kidney injury. J Am Soc Nephrol. 2008;19: 486-494.
44. Vomastek T, Schaeffer HJ, Tarcsafalvi A, Smolkin ME, Bissonette EA, Weber MJ. Modular construction of a signaling scaffold: MORG1 interacts with components of the ERK cascade and links ERK signaling to specific agonists. Proc Natl Acad Sci USA. 2004; 101:6981-6986.
45. Kolch W. Coordinating ERK/MAPK signalling through scaffolds and inhibitors. Nat Rev Mol Cell Biol. 2005;6:827-837.
46. Wolf G. Angiotensin II as a renal growth factor. Contrib Nephrol. 2001;(135):92-110.
47. Xu ZG, Yoo TH, Ryu DR, et al. Angiotensin II receptor blocker inhibits p27Kip1 expression in glucose-stimulated podocytes and in diabetic glomeruli. Kidney Int. 2005;67:944-952.
48. Wolf G. Growth factors and the development of diabetic nephropathy. Curr Diab Rep. 2003;3:485-490.
49. Kimura T, Takamatsu J, Ikeda K, Kondo A, Miyakawa T, Horiuchi S. Accumulation of advanced glycation end products of the Maillard reaction with age in human hippocampal neurons. Neurosci Lett. 1996;208:53-56.
50. Wang M, Takagi G, Asai K, et al. Aging increases aortic MMP-2 activity and angiotensin II in nonhuman primates. Hypertension. 2003;41:1308-1316.
51. Bucciarelli LG, Kaneko M, Ananthakrishnan R, et al. Receptor for advanced-glycation end products: key modulator of myocardial ischemic injury. Circulation. 2006;113:1226-1234.
52. Schiekofer S, Andrassy M, Chen J, et al. Acute hyperglycemia causes intracellular formation of CML and activation of ras, p42/44 MAPK, and nuclear factor κB in PBMCs. Diabetes. 2003;52:621-633.
53. Tanji N, Markowitz GS, Fu C, et al. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol. 2000;11:1656-1666.
54. Pichiule P, Chavez JC, Schmidt AM, Vannucci SJ. Hypoxia-inducible factor-1 mediates neuronal expression of the receptor for advanced glycation end products following hypoxia/ischemia. J Biol Chem. 2007;282:36330-36340.
55. Ruster C, Bondeva T, Franke S, Tanaka N, Yamamoto H, Wolf G. Angiotensin II upregulates RAGE expression on podocytes: role of AT2 receptors. Am J Nephrol. 2009;29:538-550.
56. Guo J, Ananthakrishnan R, Qu W, et al. RAGE mediates podocyte injury in adriamycin-induced glomerulosclerosis. J Am Soc Nephrol. 2008;19:961-972.